FDA Approves FluMist for Prevention of Influenza
FluMist is a live trivalent nasally administered vaccine intended for active immunization for the prevention of influenza.
Posted: June 2003
Related articles
- FluMist Approved for Self-Administration in the US - September 20, 2024
- FDA Approves FluMist Quadrivalent Vaccine to Prevent Seasonal Influenza - March 1, 2012
- FDA Approves Expanded Label for FluMist to Include Children Two to Five Years of Age - September 19, 2007
- FDA Advisory Committee Recommends Expanded Use of FluMist - May 16, 2007
- FDA Approves MedImmune's Refrigerated Formulation of FluMist - January 9, 2007
FluMist (Influenza Virus Vaccine, Live, Intranasal) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.